Facet Joint SyndromeNCT06204952
Effectiveness of Joins® for Managing Lumbar Facetogenic Pain
A study testing Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract) in people with Facet Joint Syndrome, run by Jeeyoun Moon.
Trial summary
Obtain informed consent from patients with lumbar facet joint syndrome and, after enrollment, randomly assign them to Group A (Joins®) or Group B (Placebo). According to the allocation in each group, participants are instructed to take Joins® 200mg 1 tablet three times a day or placebo 1 tablet three times a day from… Read more about this study
- Who is it for?
- Ages 19 to 80 years
- Conditions the study is for
- Facet Joint Syndrome
- What is being tested?
- Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 76 participants
- Where
- No sites listed yet
- Study dates
- 22 Jun 2024to 20 Apr 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults between 19 and 80 years of age
- Those diagnosed with lumbar facet joint syndrome through diagnostic posterior medial limb block
- Those with an average 11-point numeric rating scale (NRS) of 4 or more for back pain over the past 24 hours
- Those who voluntarily decided to participate in the study and gave written consent
Who cannot join
- Patient refusal
- If the main cause of the current back pain is infectious spondyloarthrosis/arthropathy, ankylosing spondylitis, or stenosis, or if the patient complains or shows signs of local neurological symptoms (e.g., decreased motor power in the lower extremities) due to the underlying disease.
- Patients with moderate to severe lumbar instability requiring surgery
- Cognitive decline to the point where the numeric pain rating (NRS) cannot be understood.
- Severe cardiovascular disease (Systolic BP >=160 mm Hg or diastolic BP >=100 mm) or liver (AST/APT increased more than twice normal) or kidney disease (GFR<60 mL/min/1.73 m2) A person with teeth
- Those with systemic infection or spinal infection
Show all 16Show fewer
- Those who are allergic to clinical trial drugs or their ingredients
- People with genetic problems such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption
- If you are pregnant or breastfeeding. For women of childbearing potential, those who are unwilling to use a reliable method of contraception during the administration period and for more than 4 weeks after the last administration of the investigational drug
- Women who have had menarche and have not reached postmenopausal status (≥12 months of consecutive amenorrhea without an identified cause other than menopause) and who have not undergone surgical sterilization (ovarian and/or hysterectomy) are considered women of childbearing potential.
- You must remain abstinent (abstain from sexual intercourse with the opposite sex) or use two medically acceptable forms of contraception. One method of contraception with a low failure rate, defined as less than 1% per year (e.g., oral contraceptives or intrauterine device), and a medically acceptable second method, such as spermicide and condom use by the male partner, should be used. Barrier methods alone are not permitted. Male subjects should use condoms and spermicides during sexual intercourse, and female contraceptive partners should also be careful to use at least one additional method of contraception with a low failure rate as defined above.
- The reliability of sexual abstinence must be evaluated considering the clinical trial period and the test subject's preferred daily lifestyle habits. Periodic abstinence (e.g., date, ovulation, symptom-temperature, or post-ovulation abstinence) and external ejaculation are not acceptable methods of contraception.
- Those with malignant tumor in the lumbar region
- Those who have previously undergone lumbar surgery or are scheduled to undergo spine surgery within 12 weeks after screening
- Subjects who participated in other clinical trials within 6 months before the first administration of the investigational drug
- Other people who are not suitable for this clinical trial according to the researcher's judgment
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Effectiveness of Joins® for Managing Lumbar Facetogenic Pain: A Prospective, Randomized, Double-blind, Placebo-controlled, Pilot Study
Obtain informed consent from patients with lumbar facet joint syndrome and, after enrollment, randomly assign them to Group A (Joins®) or Group B (Placebo). According to the allocation in each group, participants are instructed to take Joins® 200mg 1 tablet three times a day or placebo 1 tablet three times a day from day 1. Research subjects visit at 4-week intervals a total of 3 times (4 weeks, 8 weeks, 12 weeks) to collect various measurement variables. Both the test and control groups are observed during the period of taking the investigational medication without any changes or additional facet joint-related procedures (medial branch block, facet joint block). Acetaminophen is allowed as a rescue medication.
Read the detailed description
First Visit (-4 weeks to 0 weeks, Screening Visit)
Check the most severe and average 11-point NRS pain scores in the last 24 hours, as well as the current 11-point NRS pain score. (To be eligible for the study, the average 11-point NRS pain score in the last 24 hours should be 4 or higher.) Conduct demographic survey, confirm concurrent medications and treatments, review medical and surgical history, and perform a physical examination. Measure vital signs. Conduct laboratory tests, and for fertile women, perform a pregnancy test. Perform lumbar X-ray examination. Perform lumbar MRI examination. (This examination can be arranged in advance at an external hospital for the purpose of this study.)
Second Visit (0 weeks, Enrollment and Randomization Visit)
After confirming the laboratory tests and lumbar X-ray conducted during the last visit, proceed with randomization only if deemed eligible for the study. Measure vital signs. Check the most severe and average 11-point NRS pain scores in the last 24 hours, as well as the current 11-point NRS pain score. Self-assess the questionnaires collected during this visit. Oswestry Disability Index (ODI), PainDETECT, GAD-7, EQ-5D Prescribe the test drug and placebo. Subjects will administer the test drug as follows from the day after the visit:
Placebo Group: Administer placebo orally three times a day, one tablet per dose, for 12 weeks.
Test Group: Administer Joins® 200 mg orally three times a day, one tablet per dose, for 12 weeks.
Confirm concurrent medications and treatments, and check for adverse reactions.
Third and Fourth Visits (4 weeks/8 weeks, Treatment Visits)
Measure vital signs. Check the most severe and average 11-point NRS pain scores in the last 24 hours, as well as the current 11-point NRS pain score. Self-assess the questionnaires collected during this visit. Oswestry Disability Index (ODI) Subjects return the remaining medication after administration. Confirm compliance and prescribe new test drugs. Confirm concurrent medications and treatments, and check for adverse reactions.
Fifth Visit (12 weeks, End of Treatment Visit)
Measure vital signs. Check the most severe and average 11-point NRS pain scores in the last 24 hours, as well as the current 11-point NRS pain score. Self-assess the questionnaires collected during this visit. Oswestry Disability Index (ODI), PainDETECT, GAD-7, EQ-5D, PGIC, Satisfaction with Investigational Medication Subjects return the remaining medication after administration.
Confirm compliance. Confirm concurrent medications and treatments, and check for adverse reactions. Conduct laboratory tests, and for fertile women, perform a pregnancy test.
Sixth Visit (13 weeks, Post-Treatment Follow-up Visit)
Measure vital signs. Check for adverse reactions. Conduct laboratory tests, and for fertile women, perform a pregnancy test.
- Conditions
- Facet Joint Syndrome
- Being tested
- Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract), Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract)Drug
In patients with facet joint syndrome, Joins® (Clematidis Radix, Trichosanthes Root, Prunella Spike Extract) is administered at a dosage of 1 tablet three times a day for 12 weeks.
PlaceboDrug
In patients with facet joint syndrome, placebo drug is administered at a dosage of 1 tablet three times a day for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Take placebo drug 1T tid for 12 weeks. Receives: Drug: Placebo |
| Test drug | Active comparator | Take Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract) 1T tid for 12 weeks. Receives: Drug: Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison between two groups of change (%) in 11-point NRS
Comparison between two groups of change (%) in 11-point NRS at 12 week visits compared to baseline
Measured: 12 weeks after the baseline
Secondary outcomes (6)
Comparison between two groups of change (%) in 11-point NRS
Comparison between two groups of change (%) in 11-point NRS at 4- and 8-week visits compared to baseline
Measured: 4 weeks and 8 weeks after the baseline
Within-group comparison of change (%) in 11-point NRS
Within-group comparison of change (%) in 11-point NRS at 4-, 8-, and 12-week visits compared to baseline
Measured: 4 weeks, 8 weeks and 12 weeks after the baseline
Oswestry disability index (ODI)
Oswestry disability index (ODI): Comparison of changes (%) and absolute values at 4-, 8-, and 12-week visits compared to baseline between and within groups (0-45)
Measured: 4 weeks, 8 weeks and 12 weeks after the baseline
PainDETECT/GAD-7/EQ-5D
PainDETECT/GAD-7/EQ-5D: Comparison of changes (%) and absolute values at the 12-week visit compared to baseline between groups and by time point within groups (0-45)
Measured: 4 weeks, 8 weeks, and 12 weeks after the baseline
Patient's Satisfaction of pain
Satisfaction with PGIC and clinical investigational drugs (%)
Measured: 12 weeks after the baseline
Patient's medication
Patient's medication (comparison between groups regarding stable regimen, number of rescue medications taken, and dose taken)
Measured: 12 weeks after the baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2024
- Study start22 Jun 2024 (estimated)
- Primary completion20 Jan 2026 (estimated)
- Study completion20 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Facet Joint SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 76 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jeeyoun Moon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Jeeyoun Moon, Seoul National University
- Investigators
- Jee Youn Moon, MD, PhD, Principal investigator, Seoul National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06204952
- Sponsor's protocol ID
- 2309-118-1470
- Status last verified
- May 2024
- First submitted
- 3 Jan 2024
- Last updated
- 29 May 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Manchikanti L, Pampati V, Fellows B, Bakhit CE. Prevalence of lumbar facet joint pain in chronic low back pain. Pain Physician. 1999 Oct;2(3):59-64.
PubMed 16906217Manchikanti L, Boswell MV, Singh V, Pampati V, Damron KS, Beyer CD. Prevalence of facet joint pain in chronic spinal pain of cervical, thoracic, and lumbar regions. BMC Musculoskelet Disord. 2004 May 28;5:15. doi: 10.1186/1471-2474-5-15.
PubMed 15169547Cohen SP, Raja SN. Pathogenesis, diagnosis, and treatment of lumbar zygapophysial (facet) joint pain. Anesthesiology. 2007 Mar;106(3):591-614. doi: 10.1097/00000542-200703000-00024.
PubMed 17325518Enthoven WT, Roelofs PD, Deyo RA, van Tulder MW, Koes BW. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016 Feb 10;2(2):CD012087. doi: 10.1002/14651858.CD012087.
PubMed 26863524Abraham NS, Castillo DL, Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2008 Jul;28(1):97-106. doi: 10.1111/j.1365-2036.2008.03706.x. Epub 2008 Apr 7.
PubMed 18397385Lung YB, Seong SC, Lee MC, Shin YU, Kim DH, Kim JM, Jung YK, Ahn JH, Seo JG, Park YS, Lee CS, Roh KJ, Han CK, Cho YB, Chang DY, Kwak WJ, Jung KO, Park BJ. A four-week, randomized, double-blind trial of the efficacy and safety of SKI306X: a herbal anti-arthritic agent versus diclofenac in osteoarthritis of the knee. Am J Chin Med. 2004;32(2):291-301. doi: 10.1142/S0192415X04001941.
PubMed 15315266Choi JH, Choi JH, Kim DY, Yoon JH, Youn HY, Yi JB, Rhee HI, Ryu KH, Jung K, Han CK, Kwak WJ, Cho YB. Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model. Osteoarthritis Cartilage. 2002 Jun;10(6):471-8. doi: 10.1053/joca.2002.0526.
PubMed 12056850Kim JI, Choi JY, Kim KG, Lee MC. Efficacy of JOINS on Cartilage Protection in Knee Osteoarthritis: Prospective Randomized Controlled Trial. Knee Surg Relat Res. 2017 Sep 1;29(3):217-224. doi: 10.5792/ksrr.17.004.
PubMed 28854768Sae-Jung S, Jirarattanaphochai K. Outcomes of lumbar facet syndrome treated with oral diclofenac or methylprednisolone facet injection: a randomized trial. Int Orthop. 2016 Jun;40(6):1091-8. doi: 10.1007/s00264-016-3154-y. Epub 2016 Mar 18.
PubMed 26987980Cohen SP, Moon JY, Brummett CM, White RL, Larkin TM. Medial Branch Blocks or Intra-Articular Injections as a Prognostic Tool Before Lumbar Facet Radiofrequency Denervation: A Multicenter, Case-Control Study. Reg Anesth Pain Med. 2015 Jul-Aug;40(4):376-83. doi: 10.1097/AAP.0000000000000229.
PubMed 26066382